Teva: UBS upgrades to 'buy'
(CercleFinance.com) - UBS has upgraded its rating on the Teva Pharmaceuticals stock from "neutral" to "buy," inching up its target price from 23 dollars to 24 dollars, which suggests upside potential of 28% for this Israeli pharmaceutical company.
"Deep analysis of TEVA's financials and new growth assets give us confidence that deleveraging will lead to stock outperformance," the broker summarises in its research note.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
"Deep analysis of TEVA's financials and new growth assets give us confidence that deleveraging will lead to stock outperformance," the broker summarises in its research note.
Copyright (c) 2019 CercleFinance.com. All rights reserved.